Tero Satomaa

This inventor holds 18 USPTO granted patents and 31 published patent applications, plus 1 CIPO patent and 14 EPO patents, primarily in Glycoprotein Conjugates. Top assignees: Glykos Finland Oy, Suomen Punainen Risti Veripalvelu, Glykos Finland. Active years: 2012-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tero Satomaa. Retrieved from https://idiyas.com/inventor/tero-satomaa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 31)

% Patents Active = 33.3

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 14 (Patent Applications = 26)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 24(Granted Patents)

Company Filing History:

Suomen Punainen Risti Veripalvelu

where one patent can have more than one assignee

Years Active: 2012-2023

Loading Chart...

Areas of Expertise:

Hydrophilic Linkers

Glycoprotein

Toxic Payload

Conjugates

Cell Populations

Carbohydrate Profiles

Tumor Specific Oligosaccharides

Enzymatical Modification

Cancer Specific Sequences

Serum Albumin

Glycosylation

Analytical Methods

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11793886 - Hydrophilic linkers and conjugates thereof (2023-10-24),

2. 11723983 - Conjugates of a glycoprotein or a glycan with a toxic payload (2023-08-15),

3. 10973922 - Glycoprotein-toxic payload conjugates (2021-04-13),

4. 10973920 - Saccharide derivative of a toxic payload and antibody conjugates thereof (2021-04-13),

5. 10000734 - Method for evaluating cell populations (2018-06-19),

6. 9464137 - Glycoprotein (2016-10-11),

7. 9410126 - Carbohydrate profile compositions from human cells and methods for analysis and modification thereof (2016-08-09),

8. 9382512 - Method for evaluating cell populations (2016-07-05),

9. 9234169 - Enzymatical modification of cell glycosylation using serum albumin and divalent cations (2016-01-12),

10. 8759005 - Tissue carbohydrate compositions and analysis thereof (2014-06-24),

11. 8703488 - Culture of cells (2014-04-22),

12. 8697061 - Tumor specific oligosaccharide epitopes and use thereof (2014-04-15),

13. 8691774 - Carbohydrate profile compositions from human cells and methods for analysis and modification thereof (2014-04-08),

14. 8546353 - Compounds and combinations (2013-10-01),

15. 8440457 - Method of profiling a cell population (2013-05-14),

Title: Tero Satomaa: A Vanguard in Innovative Biotechnology

Introduction

Tero Satomaa, based in Helsinki, Finland, is a notable figure in the field of biotechnology, recognized for his contributions as an inventor. With a remarkable portfolio of 18 patents, Satomaa has made significant strides in the development of innovative medical solutions.

Latest Patents

Among his latest inventions, Tero Satomaa has developed crucial advancements in the realm of hydrophilic linkers and their conjugates. His patents disclose novel hydrophilic linkers and their conjugates, which are pivotal in advancing pharmaceutical applications. Moreover, one of his groundbreaking inventions encapsulates a glycoprotein or glycan conjugated with a toxic payload. This innovation not only describes the conjugate but also outlines a pharmaceutical composition and methods to modulate cell growth and treat tumor cells, marking a revolutionary step in cancer therapy.

Career Highlights

Tero Satomaa's career has been defined by his impactful work at several notable companies. He has worked with Glykos Finland Oy, where he contributed significantly to the biopharmaceutical realm. Furthermore, his tenure at the Finnish Red Cross Blood Service allowed him to apply his inventions to real-world medical settings, enhancing healthcare solutions.

Collaborations

Throughout his career, Tero has collaborated with notable professionals, including colleagues Jari Natunen and Juhani Saarinen. These partnerships have not only fostered creativity and innovation but have also resulted in groundbreaking advancements in biotechnology.

Conclusion

Tero Satomaa stands out as a prominent inventor in the biotechnology sector, particularly with his extensive patent portfolio and commitment to improving medical practices. His work continues to influence the future of pharmaceutical development and cancer treatment, solidifying his reputation as a leading innovator in his field.

Profile summary based on public USPTO records.